4//SEC Filing
Perros Manoussos 4
Accession 0001104659-22-023781
CIK 0001724344other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 4:04 PM ET
Size
24.3 KB
Accession
0001104659-22-023781
Insider Transaction Report
Form 4
Perros Manoussos
DirectorPresident and CEO
Transactions
- Award
Employee Stock Option (Right to Buy)
2021-07-16+58,307→ 58,307 totalExercise: $2.44Exp: 2031-07-15→ Common Stock (58,307 underlying) - Award
Employee Stock Option (Right to Buy)
2021-07-16+44,276→ 44,276 totalExercise: $2.44Exp: 2031-07-15→ Common Stock (44,276 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2021-07-16−87,462→ 0 totalExercise: $4.98Exp: 2025-08-11→ Common Stock (87,462 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2021-07-16−166,623→ 0 totalExercise: $6.85Exp: 2028-04-30→ Common Stock (166,623 underlying) - Award
Employee Stock Option (Right to Buy)
2021-07-16+95,000→ 95,000 totalExercise: $2.44Exp: 2031-07-15→ Common Stock (95,000 underlying) - Award
Employee Stock Option (Right to Buy)
2021-07-16+128,531→ 128,531 totalExercise: $2.44Exp: 2031-07-15→ Common Stock (128,531 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2021-07-16−79,698→ 0 totalExercise: $15.00Exp: 2028-09-24→ Common Stock (79,698 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2021-07-16−123,500→ 0 totalExercise: $5.66Exp: 2029-01-17→ Common Stock (123,500 underlying)
Footnotes (12)
- [F1]The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option will vest on May 13, 2016, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date.
- [F10]The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option shall vest on January 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- [F11]On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 123,500 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 95,000 shares of issuer's common stock, having an exercise price of $2.44 per share.
- [F12]Eighty-five (85%) of this award will vest on July 16, 2022, and one-seventh of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.
- [F2]On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 87,462 shares of issuer's common stock granted to the Reporting Person on August 11, 2015. In exchange, the Reporting Person received a replacement option for 58,307 shares of issuer's common stock, having an exercise price of $2.44 per share.
- [F3]The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.
- [F4]The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option will vest on December 6, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date.
- [F5]On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 166,623 shares of issuer's common stock granted to the Reporting Person on May 1, 2018. In exchange, the Reporting Person received a replacement option for 128,531 shares of issuer's common stock, having an exercise price of $2.44 per share.
- [F6]The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.
- [F7]The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option shall vest on September 25, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- [F8]On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 79,698 shares of issuer's common stock granted to the Reporting Person on September 25, 2018. In exchange, the Reporting Person received a replacement option for 44,276 shares of issuer's common stock, having an exercise price of $2.44 per share.
- [F9]Ninety-four (94%) of this award will vest on July 16, 2022, and one-third of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.
Documents
Issuer
Entasis Therapeutics Holdings Inc.
CIK 0001724344
Entity typeother
Related Parties
1- filerCIK 0001751832
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 4:04 PM ET
- Size
- 24.3 KB